The emergence of pharmacotherapies for cognitive function in Down syndrome.
Kennedy Krieger Institute, Neurology and Developmental Medicine, Baltimore, Maryland 21205, USA. capone@kennedykrieger.org
George T
GT
Capone
D000293:Adolescent; D002648:Child; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003071:Cognition / Q000187:drug effects*; D000077265:Donepezil; D004305:Dose-Response Relationship, Drug; D004314:Down Syndrome / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology*; D004361:Drug Tolerance; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D009483:Neuropsychological Tests; D010880:Piperidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil